Aptose Biosciences Inc (APTO)

$1.231

-0.04

(-3.07%)

Market is closed - opens 7 PM, 22 Apr 2024

Performance

  • $1.23
    $1.29
    $1.23
    downward going graph

    0.0%

    Downside

    Day's Volatility :4.28%

    Upside

    4.28%

    downward going graph
  • $1.20
    $8.70
    $1.23
    downward going graph

    2.44%

    Downside

    52 Weeks Volatility :86.21%

    Upside

    85.86%

    downward going graph

Returns

PeriodAptose Biosciences Inc
3 Months
-37.51%
6 Months
-45.77%
1 Year
-82.9%
3 Years
-98.29%

Highlights

Market Capitalization
20.1M
Book Value
- $0.36
Earnings Per Share (EPS)
-7.58
PEG Ratio
0.0
Wall Street Target Price
12.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-102.23%
Return On Equity TTM
-293.96%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-52.3M
Diluted Eps TTM
-7.58
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.27
EPS Estimate Next Year
-2.72
EPS Estimate Current Quarter
-1.59
EPS Estimate Next Quarter
-0.88

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Aptose Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 874.82%

Current $1.23
Target $12.00

Technicals Summary

Sell

Neutral

Buy

Aptose Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • DRW Securities, LLC

    3.77%
  • Nantahala Capital Management, LLC

    1.53%
  • Carlson Capital LP

    0.62%
  • Morgan Stanley - Brokerage Accounts

    0.57%
  • Sigma Planning Corp

    0.48%
  • Cetera Advisors LLC

    0.16%

Company Information

aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt

Organization
Aptose Biosciences Inc
Employees
35
CEO
Dr. William G. Rice Ph.D.
Industry
Health Technology

FAQs